

doi: 10.12336/bmt.corr121925

This Correction Notice addresses amendments to the conflicts of interest statements in several articles published in Volume 5 (2024) of *Biomaterials Translational*. These articles were authored by scholars serving on the journal's editorial board, including the Editor-in-Chief and Editorial Board Members. However, the articles did not explicitly state that these individuals were not involved in the peer-review or decision-making processes. The updated conflicts of interest statements for the affected articles are provided below:

Correction 1

Guo H, Guo M, Xia Z, Shao Z. Membrane-coated nanoparticles as a biomimetic targeted delivery system for tumour therapy. *Biomater Transl.* 2024;5(1):33-45. doi: 10.12336/biomatertransl.2024.01.004

The updated conflicts of interest statement is as follows:

Zhidao Xia and Zengwu Shao serve as the Associate Editor and the Editor-in-Chief of *Biomaterials Translational*, respectively. They were not involved in the editorial review or the decision-making process for this article. All authors declare that there are no competing interests.

Correction 2

Ren X, Xu R, Xu C, Su J. Harnessing exosomes for targeted therapy: Strategy and application. *Biomater Transl.* 2024;5(1):46-58. doi: 10.12336/biomatertransl.2024.01.005

The updated conflicts of interest statement is as follows:

Chenjie Xu and Jiacan Su serve as the Associate Editor and the Executive Editor-in-Chief of *Biomaterials Translational*, respectively. They were not involved in the editorial review or the decision-making process for this article. All authors declare that there are no competing interests.

Correction 3

Yang H, Zheng M, Zhang Y, *et al.* Enhanced angiogenesis in porous poly(ϵ -caprolactone) scaffolds fortified with methacrylated hyaluronic acid hydrogel after subcutaneous transplantation. *Biomater Transl.* 2024;5(1):59-68. doi: 10.12336/biomatertransl.2024.01.006

The updated conflicts of interest statement is as follows:

Chenjie Xu serves as an Associate Editor of *Biomaterials Translational* and was not involved in the editorial review or the decision-making process for this article. All authors declare that there are no competing interests.

Correction 4

Liang Q, Cheng Z, Qin L. Advanced nanoparticles in osteoarthritis treatment. *Biomater Transl.* 2024;5(2):95-113. doi: 10.12336/biomatertransl.2024.02.002

The updated conflicts of interest statement is as follows:

Ling Qin serves as an Editorial Board Member of *Biomaterials Translational* and was not involved in the editorial review or the decision-making process for this article. All authors declare that there are no competing interests.

Correction 5

Wang Y, Hou Y, Hao T, *et al.* Model construction and clinical therapeutic potential of engineered cardiac organoids for cardiovascular diseases. *Biomater Transl.* 2024;5(4):337-354. doi: 10.12336/biomatertransl.2024.04.002

The updated conflicts of interest statement is as follows:

Junjie Xiao serves as an Editorial Board Member of *Biomaterials Translational* and was not involved in the editorial review or the decision-making process for this article. All authors declare that there are no competing interests.

Correction 6

Zhang C, Jing Y, Wang J, *et al.* Skeletal organoids. *Biomater Transl.* 2024;5(4):390-410. doi: 10.12336/biomatertransl.2024.04.005

The updated conflicts of interest statement is as follows:

Zhidao Xia and Jiacan Su serve as the Associate Editor and the Executive Editor-in-Chief of *Biomaterials Translational*, respectively. They were not involved in the editorial review or the decision-making process for this article. All authors declare that there are no competing interests.

Available online: December 31, 2025